ICTRP Search Portal

Main

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.

Register:	ClinicalTrials.gov
Last refreshed on:	12 December 2020
Main ID:	NCT03426956
Date of registration:	02/02/2018
Prospective Registration:	Yes
Primary sponsor:	Hvidovre University Hospital
Public title:	Glucose Absorption and Gut Hormone Secretion After Gastric Bypass
Scientific title:	Impact of Canaglifloxin on Gut Hormone Secretion After Gastric Bypass
Date of first enrolment:	February 8, 2018
Target sample size:	10
Recruitment status:	Unknown status
URL:	https://clinicaltrials.gov/show/NCT03426956
Study type:	Interventional
Study design:	Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Basic Science. Masking: Single (Participant).
Phase:	N/A

Countries of recruitment
Denmark

Contacts

Name:	Christoffer Martinussen, MD
Address:
Telephone:	+4538623032
Email:	christoffer.martinussen@regionh.dk
Affiliation:

Name:	Sten Madsbad, Professor
Address:
Telephone:	+4538623032
Email:	sten.madsbad@regionh.dk
Affiliation:

Key inclusion & exclusion criteria

Inclusion Criteria:

•Uncomplicated gastric bypass surgery performed minimum 12 months prior to study

Exclusion Criteria:

- Type 1 or 2 diabetes mellitus prior to or after gastric bypass surgery

- Pregnancy or breastfeeding

- Haemoglobin levels below 6,5 mM

Age minimum: 18 Years
Age maximum: 75 Years
Gender: All

Health Condition(s) or Problem(s) studied

Overweight

Intervention(s)

Dietary Supplement: Glucose + Canagliflozin

Dietary Supplement: Glucose

Primary Outcome(s)

Difference in GLP-1 secretion (evaluated by iAUC). [Time Frame: 0-240 min following glucose ingestion]

Secondary Outcome(s)

Difference in C-peptide responses between the two test days. [Time Frame: 0-240 min following glucose ingestion]

Difference in cholecystokinin (CCK) responses (evaluated by iAUC) between the two test days. [Time Frame: 0-240 min following glucose ingestion]

Difference in Gastric Inhibitory Peptide (GIP) responses (evaluated by iAUC) between the two test days. [Time Frame: 0-240 min following glucose ingestion]

Difference in glucose responses between the two test days. [Time Frame: 0-240 min following glucose ingestion]

Difference in oxyntomodulin responses (evaluated by iAUC) between the two test days. [Time Frame: 0-240 min following carbohydrate ingestion]

Difference in glucagon responses (evaluated by iAUC) between the two test days. [Time Frame: 0-240 min following glucose ingestion]

Difference in bile acid responses (evaluated by iAUC) between the two test days. [Time Frame: 0-240 min following glucose ingestion]

Difference in insulin responses between the two test days. [Time Frame: 0-240 min following glucose ingestion]

Difference in peptide YY (PYY) responses (evaluated by iAUC) between the two test days. [Time Frame: 0-240 min following carbohydrate ingestion]

Secondary ID(s)

CM-CANA-18

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Ethics review

Results

Results available:
Date Posted:
Date Completed:
URL:

Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.